TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06679894

Intervention type: PROCEDURE
Intervention: Implant site preparation with osteotomes and electrified mallet
Description: Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~A pilot osteotome (100-P) was used to easily perforate the cortical plate. Subsequently, osteotomes with gradually increasing diameters were employed until the final diameter of 3.2 mm was reached.~The sequence of osteotomes and their respective diameters were as follows:~1. Osteotome 100-P: At a height of 8.5 mm, the diameter was 2.2 mm;~2. Osteotome 160: At a height of 8.5 mm, the diameter was 2.8 mm;~3. Osteotome 200: At a height of 8.5 mm, the diameter was 3.2 mm. Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment.

Intervention type: PROCEDURE
Intervention: Implant site preparation with osseodensification drills
Description: Under local anesthesia (mepivacaine HCL 2% with epinephrine1:100.000), a minimally invasive full-thickness flap was elevated to expose the alveolar crest.~The implant site preparation was realized using osseodensification burs at a rotation speed of 1200 rpm. The osseodensification burs sequence was as follows:~1. Initial pilot hole (rotated clockwise);~2. WT1828 bur (rotated counterclockwise),~3. WT2838 bur (rotated counterclockwise). Implant (4.0x8.5 mm; Anyridge, Megagen, Gyeongbuk, South Korea) was positioned using a surgical motor.~A 3 mm high transepithelial abutment (OCTA, Megagen, Gyeongbuk, South Korea) was connected to it using a torque wrench and it was tightened to 30 Ncm.~Single sutures in monofilament synthetic polypropylene 4.0 were performed to close flaps around the abutment.
Study: NCT06680765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison group
Description: These are behavioural interventions delivered by trained HEWs or Health providers at primary care facilities (PHCs in Nigeria and Health posts in Ethiopia).
Study: NCT06680050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: Durvalumab will be administered via IV infusion at a dose of 1500 mg on day 8 Q4W until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
Study: NCT06147414

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: A blood sample (50 ml) will be taken in care of prenatal diagnosis and 40 ml will be used for study.~The 40 mL of blood needed for the research will be collected on BCT tubes (4 tubes).~During the study, in centers, the plasma samples will be stored at room temperature and will be sent to the laboratory within 24 hours (no centrifugation in centers).~The plasma samples will be then temporarily stored at -80°C in each co-investigating laboratory under the supervision of lab supervisor until the analysis. cfDNA will be extracted from the whole plasma sample before each sequencing run and stored à +4°C until the cfDNA sequencing.

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: A blood sample (50 ml) will be taken in care of prenatal diagnosis and 40 ml will be used for study.~The 40 mL of blood needed for the research will be collected on BCT tubes (4 tubes).~During the study, in centers, the plasma samples will be stored at room temperature and will be sent to the laboratory within 24 hours (no centrifugation in centers).~The plasma samples will be then temporarily stored at -80°C in each co-investigating laboratory under the supervision of lab supervisor until the analysis. cfDNA will be extracted from the whole plasma sample before each sequencing run and stored à +4°C until the cfDNA sequencing.
Study: NCT06090890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Add 0.5mg QD orally and start using it within 48 hours after intervention.
Study: NCT06680050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Ceralasertib dose will be administered orally, 240mg BID, approximately 12 ± 2 hours apart, days 1 to 7 q28 (Q4W), up to progression or unacceptable toxicity.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Loco-regional recurrences of the primary tumor and regional lymph node metastases will be treated with a total dose of 36 to 50 Gy in daily fractions with a dose of 2 to 3 Gy per fraction. Two weeks from the last dose of radiotherapy, a systemic treatment with durvalumab and ceralasertib will be started.
Study: NCT05376449

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HealthPartners NeuroWell Exercise Program
Description: A 12-week exercise program geared towards individuals with neurological disorders or injuries run by the Regions Hospital Rehabilitation department at the HealthPartners Neuroscience Center. The exercise programming will be designed by the exercise physiologists and adapted to individuals' abilities. Exercise prescriptions will be designed based on established guidelines, level and completeness of injury, individual functional ability, individual goals, and baseline exercise assessments. Program will consist of strength and endurance adaptive exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthPartners NeuroWell Exercise Program
Description: A 12-week exercise program geared towards individuals with neurological disorders or injuries run by the Regions Hospital Rehabilitation department at the HealthPartners Neuroscience Center. The exercise programming will be designed by the exercise physiologists and adapted to individuals' abilities. Exercise prescriptions will be designed based on established guidelines, level and completeness of injury, individual functional ability, individual goals, and baseline exercise assessments. Program will consist of strength and endurance adaptive exercise.
Study: NCT06629207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT with 18-FDG
Description: FDG-PET scans will be acquired in a Siemens Biograph Vision Quadra PET/CT (Siemens, Germany) at 30-minute post-injection of approximately 80 MBq 18F-FDG. The duration of the acquisition is 20 minutes. The PET images will be reconstructed with the vendor's time of flight (TOF) point-spread-function (PSF) algorithm, following corrections for randoms, scatter, and decay. Attenuation correction will be performed first using low-dose CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPECT : 123 I-FP-CIT (DATSCAN)
Description: DaT-Scans will be acquired in a GE Discovery NM/CT 670 Pro™. After injection of approximately 110 MBq 123I-FP-CIT, images will be acquired within 4 h post-injection. The duration of the acquisition is 35 minutes.
Study: NCT06090890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 0.5mg/kg QD orally and the dosage was reduced at a rate of 5mg/d per month until 5-10mg/d, maintained for 1 year after PCI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Patients who have re-implanted DES should receive aspirin for at least 1 year after intervention; Patients who have underwent DEB expansion should apply aspirin for at least 3 months after intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 Receptor Antagonist
Description: Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 Receptor Antagonist
Description: Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P2Y12 Receptor Antagonist
Description: Patients who have re-implanted DES should receive 1 P2Y12 receptor antagonist for at least 1 year after intervention; Patients who have underwent DEB expansion should apply the P2Y12 receptor antagonist for at least 3 months after intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug
Description: Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.
Study: NCT06629207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI examination to exclude structural brain anomalies.
Study: NCT06681571

Intervention type: OTHER
Intervention: TAP Block
Description: TAP block will be performed immediately after the induction of anesthesia, under ultrasond guidence.

Intervention type: OTHER
Intervention: RSB
Description: Rectus Sheath block will be performed immediately after the induction of anesthesia, under Ultrasond guidence.
Study: NCT06632691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: Use of a virtual reality headset during rectosigmoidoscopy
Study: NCT06157918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1813 oral solution (2.0g:25mg)
Description: SYHA1813 oral solution, 25mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1813 oral solution (2.0g:25mg)
Description: SYHA1813 oral solution, 25mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1813 oral solution (2.0g:25mg)
Description: SYHA1813 oral solution, 25mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1813 oral solution (20ml:200mg)
Description: SYHA1813 oral solution, 25mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1813 oral solution (20ml:200mg)
Description: SYHA1813 oral solution, 25mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1813 oral solution (20ml:200mg)
Description: SYHA1813 oral solution, 25mg, oral
Study: NCT05005910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan 20 mg oral every 12 hours (total 72 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPIs IV infusion
Description: Pantoprazole 80 mg IV loading then 8 mg/hr
Study: NCT06090890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug
Description: Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipid-lowering drug
Description: Formulate the lipid-lowering drug regimen with LDL-C\<1.4mmol/L as the target on the basis of moderate intensity or above statins.
Study: NCT05418985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly reminder message about breast self-exam.
Description: Monthly reminder message about breast self-exam.
Study: NCT05122351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration at the Quadratus Lumborum muscle Versus Paracetamol injection as analgesia in post operative Open Inguinal Hernia surgeries
Description: Comparative Study Between The Efficacy Of Quadratus Lumborum Block VS Conventional Analgesia In Patients Undergoing Open Inguinal Hernia Surgical Repair

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration at the Quadratus Lumborum muscle Versus Paracetamol injection as analgesia in post operative Open Inguinal Hernia surgeries
Description: Comparative Study Between The Efficacy Of Quadratus Lumborum Block VS Conventional Analgesia In Patients Undergoing Open Inguinal Hernia Surgical Repair
Study: NCT05131256

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurofunctional characterization of emotional regulation (fMRI)
Description: Investigation of neurofunctional characterization of emotional regulation and its links with the eating behaviours of patients suffering from obesity using a comprehensive, clinical, and cognitive assessment and task-based MRI exams.
Study: NCT05207254

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonic test
Description: Ultrasonic test to the patient's head, neck and jaw area.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonic test
Description: Ultrasonic test to the patient's head, neck and jaw area.
Study: NCT05615779

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Randomized pectin diet
Description: UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in pectin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Randomized B-fructan diet
Description: UC and healthy control participants randomized to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized pectin diet
Description: UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in pectin based on personal host (biopsy) and microbe (stool) response at baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized B-fructan diet
Description: UC and healthy control participants to receive recommendations provided by a dietician increasing consumption of foods high in B-fructan based on personal host (biopsy) and microbe (stool) response at baseline
Study: NCT05972473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Ophthalmic
Description: 2mg Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive monthes, folloesd by once every 8 weeks(Q8W).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI302
Description: 8 mg IBI302 will be administered by intraitreal injection into the study eye at intervals as specified in the study protocol.
Study: NCT06358131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: upper and lower endoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy
Description: upper and lower endoscopy
Study: NCT04796545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SING IMT(TM) System, model NG SI IMT 3X
Description: The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration.
Study: NCT05962671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid-sparing based anesthesia
Description: Intraoperative opioid-sparing maintenance comprised dexmedetomidine bolus dose of 1 mcg/kg followed by 0.3 mcg/kg/h, propofol 4-8 mg/kg/h and ketamine 25 mg/h for a max of 50 mg during the procedure, targeting bispectral index (BIS) between 45%-60%. The lean body weight will be used for calculation of the drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane-based anesthesia
Description: Intraoperative sevoflurane-based anesthesia, 0.8 to 1.0 Minimum alveolar concentration will be used combined with fentanyl 1 mcg/kg followed by 1 -2 mcg/kg/h and cis-atracurium, to keep bispectral index between 45% to 60%.
Study: NCT04789239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: SZC is an approved drug in Sweden and subsidized for patients with chronic kidney disease in stages 3 to 5, with or without chronic heart failure, for whom treatment with Resonium is not suitable and for patients with chronic heart failure without con-comitant chronic kidney disease

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with the same dose of placebo medicine as they would have received had they been treated with the interventional drug (SZC).
Study: NCT05744713

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT06064266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plant-based mild ketogenic controlled diet
Description: Plant-based mild ketogenic diet (10-20EN% carbohydrates, 10-20EN% protein, and 60-70EN% fat), consisting of a daily breakfast, lunch, dinner, and snacks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat shake
Description: The high-fat shake consists of unsweetened almond milk, sunflower oil, and plant sterols, resulting in a shake containing 885 kcal (1.5g protein, 97.3g fat, and 0.8g sugar).
Study: NCT05788900

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: intravenous Heparin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin
Description: intravenous Heparin
Study: NCT05131256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofunctional characterization of emotional regulation (fMRI)
Description: Investigation of neurofunctional characterization of emotional regulation and its links with the eating behaviours of patients suffering from obesity using a comprehensive, clinical, and cognitive assessment and task-based MRI exams.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurofunctional characterization of emotional regulation (fMRI)
Description: Investigation of neurofunctional characterization of emotional regulation and its links with the eating behaviours of patients suffering from obesity using a comprehensive, clinical, and cognitive assessment and task-based MRI exams.
Study: NCT05544812

Intervention type: DRUG
Intervention: Sintilimab ，bevcizumab/cetuximab，XELOX
Description: Patients in this group had previously received the following treatment regimens:~Oxaliplatin :130 mg/m2, D1, Q3W; Capecitabine :1000mg/m2, bid q2w Sintilimab for injection :200mg, D1, Q3W Bevacizumab :7.5mg/kg, D1, Q3W or cetuximab :500 mg/m, D1, Q2W
Study: NCT04937855

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06560190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orthopaedic Manual Physical Therapy
Description: Individualized Treatment
Study: NCT05562388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnodent Classic
Description: The efficacy of the device will be evaluated in regards to the response of nocturia. Once patients report an average of voiding per night of less than 2 in the preceding 2 weeks of the follow up they will be classified as responders in term of nocturia and will be evaluated with a second sleep study. Efficacy of MAD will be assessed by comparing the apnea hypopnea index (AHI) values of pre and post sleep study with MAD, and they will be classified as responders if they have 50% improvement in AHI.
Study: NCT05299320

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuromuscular fatigue and postural sway evaluation
Description: Neuromuscular fatigue will be established by using the Excalibur Sport Ergometer device and the Wingate Anaerobic Strength Test. Postural sway will be evaluated with Cyst Force Plate Balance device. This device is a precision device that provides objective measurable data.

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuromuscular fatigue and postural sway evaluation
Description: Neuromuscular fatigue will be established by using the Excalibur Sport Ergometer device and the Wingate Anaerobic Strength Test. Postural sway will be evaluated with Cyst Force Plate Balance device. This device is a precision device that provides objective measurable data.
Study: NCT04729439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homework Organization and Planning Skills (HOPS) Intervention
Description: A behavioral/organizational skills intervention focused on improving adolescents' homework, organization, and planning skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Homework Organization and Planning Skills (HOPS) Intervention
Description: A behavioral/organizational skills intervention focused on improving adolescents' homework, organization, and planning skills

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Health Application (Online Platform) for Encouraging Skills Practice
Description: This online platform can be used on participants' personal devices including laptops, phones, tablets, or other computers and is designed to encourage adolescent's skills practice, monitor and reward treatment progress, and optimize motivation in treatment
Study: NCT06438731

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BREAST MILK
Description: The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: KNITTED OCTOPUS
Description: The preterm will be monitored for 5 minutes before birth, during the procedure cycle, and then by camera recording for 5 minutes
Study: NCT05797623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trappa ethanolamine tablets ; ciclosporin
Description: Trappa ethanolamine tablets combined with ciclosporin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ; ciclosporin
Description: Placebo combined with ciclosporin